We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





BioFire Diagnostics’ PCR-based SARS-CoV-2 Test Receives FDA Emergency Use Authorization

By LabMedica International staff writers
Posted on 08 Oct 2020
BioMérieux’s (Marcy-l'Étoile, France) subsidiary, BioFire Diagnostics, has received Emergency Use Authorization by the US Food and Drug Administration for the BioFire Respiratory Panel 2.1-EZ which uses a syndromic approach to accurately detect and identify a wide range of pathogens, including SARS-CoV-2.

The BioFire RP2.1-EZ Panel is designed to run on the CLIA-waived BioFire FilmArray 2.0 EZ Configuration System and identifies a menu of 19 respiratory targets in one multiplex PCR test, with results in about 45 minutes. More...
Because a large number of pathogens cause respiratory infections, tests that only identify SARS-CoV-2 or influenza run the risk of missing the real culprit. With the ability to identify 15 viral and 4 bacterial respiratory pathogens, BioFire’s easy-to-use syndromic test requires just one nasopharyngeal swab and two minutes of hands-on time. The multiplex PCR BioFire RP2.1-EZ Panel provides a rapid, accurate, and comprehensive alternative to targeted testing and detects a greater number of pathogens no matter the season or the time of year.

Given the shift toward value-based care, BioFire’s syndromic testing can help reduce untimely and expensive send-out tests. The BioFire RP2.1-EZ Panel (EUA) can help reduce overall workload for urgent care clinics, helping streamline workflow, maximize throughput, decrease costs, and increase patient satisfaction.

Related Links:
BioMérieux


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: New research brings hope for improved early detection of pancreatic cancer (Photo courtesy of Adobe Stock)

New Biomarker Panel to Enable Early Detection of Pancreatic Cancer

Pancreatic cancer (PC) has one of the worst prognoses globally, with only 13% of diagnosed patients surviving for five years or more. In Ireland, there are about 900 cases of pancreatic cancer annually,... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.